Michael Hearne - Apr 14, 2022 Form 4 Insider Report for LA JOLLA PHARMACEUTICAL CO (LJPC)

Signature
/s/ Michael Hearne
Stock symbol
LJPC
Transactions as of
Apr 14, 2022
Transactions value $
$643
Form type
4
Date filed
4/18/2022, 06:31 PM
Previous filing
Apr 4, 2022
Next filing
May 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LJPC Common Stock Award $643 +173 +1.93% $3.71 9.15K Apr 14, 2022 Direct F1
holding LJPC Common Stock 9.61M Apr 14, 2022 By LP F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LJPC Employee Stock Option (Right to Buy) Award $0 +173 $0.00 173 Apr 14, 2022 Common Stock 173 $4.37 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired on 4/14/2022 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2 The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Tang Capital Management, LLC ("TCM") is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as the Chief Financial Officer of TCM. Mr. Hearne has a pecuniary interest in the shares beneficially held by TCP.
F3 The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years.